Zevra Therapeutics, Inc.

NASDAQ:ZVRA

Biotechnology

Healthcare
$9.28 +2.44%

+$0.31 today

Market cap
$552.20M
Beta
0.89
P/E (TTM)
6.1
EPS (TTM)
$2.13
52W Low $7.16High $14.27

Volume 0.62M

Average 1.43M

ZVRA EBITDA Margin

EBITDA as a percentage of revenue.

Zevra Therapeutics, Inc.NASDAQ: ZVRA

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to 120.0%

EBITDA Margin was 120.0% in Q1 FY2026, up 111.7 pp from a year earlier. On a trailing-twelve-month basis it was 114.9%, up 263.4 pp year over year. Over 3 fiscal years it widened by 343.9 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 7 analysts of 65.4% for the fiscal year ending Dec 2026, down from 92.7% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
120.0%+76.1 pp QoQ
Last fiscal yearDec 2025
92.7%+416.3 pp YoY
LTMMar 2026
114.9%+263.4 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+111.7 pp-284.9 pp-396.5 pp
1 year+416.3 pp-27.3 pp-443.5 pp
3 years+343.9 pp-45.9 pp-389.9 pp
5 years-36.1 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
92.7%
Year-over-year change
+416.3pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How ZVRA compares with its peers on the latest reported figures

  • ZVRA's LTM Mar 2026 EBITDA Margin of 114.9% is the highest of the 6 companies compared; the peer median is 10.2%.
  • Its year-over-year change of +263.4 pp is the highest of 5, against a peer median of -9.1 pp.
  • Over three fiscal years its change of +343.9 pp compares with a peer median of -17.1 pp.
ZVRA Competitors Peer median
EBITDA Margin for ZVRA and competitors
Company Period LTM level YoY 3-year change
ZVRAZevra Therapeutics, Inc.LTM Mar 2026114.9% +263.4 pp+343.9 pp
NBIXNeurocrine Biosciences, Inc.LTM Sep 202625.7% +0.3 pp+7.4 pp
JAZZJazz Pharmaceuticals plcLTM Sep 202621.0% +14.8 pp-34.0 pp
ALKSAlkermes plcLTM Sep 202610.2% -18.5 pp+17.0 pp
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026-1.9% -26.9 pp-17.1 pp
XENEXenon Pharmaceuticals Inc.FY2025-4564.7% —-3210.7 pp
PRAXPraxis Precision Medicines, Inc.FY2025— ——
GHRSGH Research PLCFY2025— ——
ANROAlto Neuroscience, Inc.FY2025— ——
MPLTMapLight Therapeutics, Inc.FY2025— ——
NMRANeumora Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding ZVRA) 10.2%-9.1 pp-17.1 pp

Competitors are the stored peer set for ZVRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue28.65M10.16M27.46M23.61M106.47M
Cost of Revenue2.06M222K2.95M7.42M16.48M
Gross Profit26.59M9.94M24.52M16.2M89.99M
Gross Margin92.8%97.8%89.3%68.6%84.5%
Research & Development10.16M19.8M39.81M42.1M12.74M
Selling, General & Admin8.7M15.04M35.09M54.87M77.62M
Operating Expenses18.86M52.5M74.12M103.2M94.22M
Depreciation & Amortization257K944K1.01M6.39M4.05M
EBITDA(7.89M)(25.53M)(43.54M)(76.4M)98.71M
EBITDA Margin-27.5%-251.2%-158.6%-323.6%92.7%
Operating Income7.73M(42.57M)(49.6M)(87M)(4.23M)
Operating Margin27.0%-418.9%-180.6%-368.5%-4.0%
Interest Income261K1.51M4.54M2.18M6.95M
Interest Expense376K335K1.5M7.35M7.98M
Other Income / Expenses(16.25M)15.76M3.56M(3.14M)90.91M
Income Before Tax(8.52M)(26.81M)(46.05M)(90.14M)86.68M
Pre-Tax Margin-29.7%-263.8%-167.7%-381.8%81.4%
Income Tax Expense34K(33K)015.37M3.45M
Net Income(8.56M)(26.77M)(46.05M)(105.51M)83.23M
Net Margin-29.9%-263.5%-167.7%-446.9%78.2%
EPS (Basic)(2.11)(0.78)(1.30)(2.28)1.40
EPS (Diluted)(2.11)(0.78)(1.30)(2.28)1.35
Weighted Avg Shares29.77M34.49M35.45M46.25M55.31M
Weighted Avg Shares (Diluted)29.77M34.49M35.45M46.25M57.26M

Zevra Therapeutics, Inc.

NASDAQ:ZVRA

Intrinsic Alpha fair value

Locked

Current Price

$9.28

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.